Interferon lambda: a new sword in cancer immunotherapy.

PubWeight™: 1.04‹?› | Rank: Top 15%

🔗 View Article (PMC 3235441)

Published in Clin Dev Immunol on December 06, 2011


Ahmed Lasfar1, Walid Abushahba, Murugabaskar Balan, Karine A Cohen-Solal

Author Affiliations

1: Department of Biochemistry and Molecular Biology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, University Hospital Cancer Center, Newark, NJ 07103, USA.

Articles citing this

Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity (2014) 2.06

NK cells require IL-28R for optimal in vivo activity. Proc Natl Acad Sci U S A (2015) 1.14

A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity. J Neural Transm (Vienna) (2013) 0.90

Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses. J Biol Chem (2012) 0.90

Respiratory syncytial virus can infect basal cells and alter human airway epithelial differentiation. PLoS One (2014) 0.88

Interferons as inducers of apoptosis in malignant cells. J Interferon Cytokine Res (2013) 0.87

Genetic Variants in Interleukin-28B Are Associated with Diabetes and Diabetes-Related Complications in Patients with Chronic Hepatitis C Virus Infection. Dig Dis Sci (2015) 0.82

The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C. Clin Dev Immunol (2012) 0.81

A discrete population of IFN λ-expressing BDCA3hi dendritic cells is present in human thymus. Immunol Cell Biol (2015) 0.80

Osteosarcoma Overview. Rheumatol Ther (2016) 0.79

Interferons and their receptors in birds: a comparison of gene structure, phylogenetic analysis, and cross modulation. Int J Mol Sci (2014) 0.78

Temperature rise after peginterferon alfa-2a injection in patients with chronic hepatitis C is associated with virological response and is modulated by IL28B genotype. J Hepatol (2013) 0.78

Structural analysis of tumor-related single amino acid mutations in human MxA protein. Chin J Cancer (2015) 0.77

Critical role of the endogenous interferon ligand-receptors in type I and type II interferons response. Immunology (2014) 0.76

IFN-λ cancer immunotherapy: new kid on the block. Immunotherapy (2016) 0.76

Interferon lambda 1 expression in cervical cells differs between low-risk and high-risk human papillomavirus-positive women. Med Microbiol Immunol (2014) 0.76

Mesenchymal stem cells are efficiently transduced with adenoviruses bearing type 35-derived fibers and the transduced cells with the IL-28A gene produces cytotoxicity to lung carcinoma cells co-cultured. BMC Cancer (2014) 0.76

Adenovirus expressing IFN-λ (Ad/hIFN-λ) produced anti-tumor effects through inducing apoptosis in human tongue squamous cell carcinoma cell. Int J Clin Exp Med (2015) 0.75

IFN-λ: A New Inducer of Local Immunity against Cancer and Infections. Front Immunol (2016) 0.75

IFN-λ Inhibits Drug-Resistant HIV Infection of Macrophages. Front Immunol (2017) 0.75

IFNλ Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism. J Invest Dermatol (2015) 0.75

Effect of Interleukin-29 on Interferon-α Secretion by Peripheral Blood Mononuclear Cells. Cell J (2015) 0.75

Interferon-lambda3 (IFN-λ3) and its cognate receptor subunits in tree shrews (Tupaia belangeri): genomic sequence retrieval, molecular identification and expression analysis. PLoS One (2013) 0.75

Articles cited by this

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16

Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A (1998) 13.39

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol (2002) 11.87

IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol (2002) 11.22

Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006) 10.05

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology (2006) 6.16

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93

Lambda interferon inhibits hepatitis B and C virus replication. J Virol (2005) 5.47

Interferons alpha and beta as immune regulators--a new look. Immunity (2001) 4.75

IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog (2008) 4.70

Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol (2006) 4.21

Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol (2002) 3.91

Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol (2002) 3.83

An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol (2008) 3.75

Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology (2006) 3.46

Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology (2010) 3.26

Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol (2004) 3.25

Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis (2005) 2.98

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology (2010) 2.87

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology (2010) 2.83

Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int (2008) 2.65

Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem (2004) 2.55

IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A (2011) 2.47

Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun (2008) 2.40

Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet (2001) 2.40

Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell (2011) 2.39

Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog (2008) 2.38

Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res (2006) 2.34

Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol (2010) 2.28

Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine (2005) 2.27

Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. Am J Pathol (2007) 2.18

Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res (2010) 2.15

IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol (2005) 2.05

Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol (2006) 2.03

Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res (2008) 2.03

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology (2010) 2.02

Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol (2009) 1.88

Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res (1987) 1.87

IL-28 and IL-29: newcomers to the interferon family. Biochimie (2007) 1.81

Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun (2009) 1.81

Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood (2006) 1.76

Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood (2009) 1.75

Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol (2009) 1.74

Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) Am J Gastroenterol (1998) 1.74

Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J Virol (2010) 1.66

Antitumor activity of IFN-lambda in murine tumor models. J Immunol (2006) 1.63

A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg (2007) 1.63

Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun (2007) 1.60

Type III IFN-lambda mRNA expression in sputum of adult and school-aged asthmatics. Clin Exp Allergy (2008) 1.56

Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol (2008) 1.50

A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther (2006) 1.48

IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther (2008) 1.45

IL-28A (IFN-λ2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med (2011) 1.44

IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol (2007) 1.35

Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis (2010) 1.28

Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29). J Leukoc Biol (2009) 1.27

Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol (2008) 1.26

Interferon lambdas: the next cytokine storm. Gut (2011) 1.25

Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun (2006) 1.24

Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res (1998) 1.24

Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets. J Virol (2009) 1.22

Regulation of apoptosis by type III interferons. Cell Prolif (2008) 1.19

Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother (2010) 1.19

Temporal and spatial resolution of type I and III interferon responses in vivo. J Virol (2010) 1.18

Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun (2006) 1.17

Hepatocellular carcinoma. Hepatology (1998) 1.16

IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood (2009) 1.15

Interferons and apoptosis. J Interferon Cytokine Res (2003) 1.15

Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin Gastroenterol Hepatol (2005) 1.12

Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res (2007) 1.11

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology (2000) 1.10

Interferon-lambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology (2008) 1.10

Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. Cancer J (2008) 1.06

IFN-gamma regulation of the type IV class II transactivator promoter in astrocytes. J Immunol (1999) 1.05

High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol (2001) 1.04

Interferon lambda inhibits herpes simplex virus type I infection of human astrocytes and neurons. Glia (2010) 1.02

The GRIMs: a new interface between cell death regulation and interferon/retinoid induced growth suppression. Cytokine Growth Factor Rev (2004) 1.01

Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J Gastrointest Surg (2003) 1.00

Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place? Carcinogenesis (2010) 0.97

Innate immunity in the pathogenesis of virus-induced asthma exacerbations. Proc Am Thorac Soc (2007) 0.96

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer (2004) 0.96

Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy. Recent Pat Anticancer Drug Discov (2008) 0.91

Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma. Oncology (2008) 0.88

A role for IFN-lambda1 in multiple myeloma B cell growth. Leukemia (2008) 0.86

Host CD4+ T lymphocytes are required for the synergistic action of interferon-alpha/beta and adoptively transferred immune cells in the inhibition of visceral ESb metastases. Cancer Res (1995) 0.84

Antitumour effects of interferons: past, present and future. Br J Haematol (1991) 0.84

[IL28 (interferon lambda3) gene polymorphisms and response to IFN-alpha treatment in patients infected with hepatitis virus C]. Med Sci (Paris) (2010) 0.81

Interaction of IFN alpha/beta with host cells essential to the early inhibition of Friend erythroleukemia visceral metastases in mice. Int J Cancer (1994) 0.81

Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T cells and IFN-alpha/beta. Int J Cancer (1994) 0.81

Liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg (2008) 0.80

Interferons in the treatment of solid tumors. Cancer Treat Res (2005) 0.80